11 March 2023: Database Analysis
Prognostic-Related Biomarkers in Pancreatic Ductal Adenocarcinoma Correlating with Immune Infiltrates Based on Proteomics
Yan-qi Kou 1ACEF* , Yu-ping Yang 1BCE* , Zhao-jie Pan 2E* , Shen-shen Du 1BC* , Wei-nan Yuan 1BC , Kun He 1E , Biao Nie 1A*DOI: 10.12659/MSM.938785
Med Sci Monit 2023; 29:e938785
Table 1 Clinicopathologic characteristics of PDAC patients.
| Characteristic | Levels | Overall |
|---|---|---|
| n | 125 | |
| Gender, n (%) | Female | 59 (47.2%) |
| Male | 66 (52.8%) | |
| Tumor grade, n (%) | G1 | 8 (6.4%) |
| G2 | 88 (70.4%) | |
| G3 | 28 (22.4%) | |
| G4 | 1 (0.8%) | |
| Tumor stage, n (%) | Stage I | 14 (11.2%) |
| Stage II | 64 (51.2%) | |
| Stage III | 40 (32%) | |
| Stage IV | 7 (5.6%) | |
| Vital status, n (%) | Alive | 43 (34.4%) |
| Dead | 82 (65.6%) | |
| Recurrence status, n (%) | No | 58 (46.4%) |
| Yes | 67 (53.6%) | |
| Cancer status, n (%) | Not reported | 17 (13.6%) |
| Tumor free | 30 (24%) | |
| With tumor | 78 (62.4%) | |
| Age, median (IQR) | 65 (60, 72) | |
| OS, median (IQR) | 448 (256, 733) | |
| RFS, median (IQR) | 348 (172, 579) |